Cost
What Tirzepatide Actually Costs in 2026
Tirzepatide now costs between a modest insurance copay and roughly $1,086 a month, and the difference is determined almost entirely by insurance status rather than by shopping around. Zepbound self-pay through the manufacturer runs $299 at the starting dose and $449 at maintenance. A small number of telehealth providers still publish verified all-in pricing below that.
Key takeaways
- Insurance status determines cost far more than provider choice does.
- Zepbound self-pay is $299 per month at 2.5 mg and $449 at 7.5 mg and above.
- Retail without coverage sits near $1,086 a month.
- Advertised telehealth prices frequently exclude mandatory membership fees.
- Because stopping causes regain, the number that matters is recurring cost over years.
| Self-pay, starting dose | $299/month |
|---|---|
| Self-pay, maintenance | $449/month |
| Retail without coverage | About $1,086/month |
| With commercial coverage | Can fall to a modest copay |
| Planning horizon | Years — stopping produces regain |
| Price verified | 2026-07-22 |
Why does the same drug cost so differently?
Because the manufacturer prices by channel rather than by product. A covered benefit routes cost through a plan and a savings card can reduce the remainder substantially. No covered benefit means paying a cash price set to compete with a market that no longer exists. The molecule is identical in every case.
This is why time spent on a coverage appeal frequently returns more than time spent comparing sellers. An appeal that succeeds can move someone from hundreds a month to tens.
| Dose | Mean reduction |
|---|---|
| 2.5 mg | 299 |
| 5 mg | 399 |
| 7.5 mg | 449 |
| 10 mg | 449 |
| 12.5 mg | 449 |
| 15 mg | 449 |
How do the remaining telehealth prices compare?
A small number of providers still publish a complete recurring price with medication included and no separate membership fee. Those are the only telehealth figures this site ranks, because a price that excludes mandatory fees is not comparable with one that includes them.
The table below shows every provider in the dataset whose recurring all-in cost can be computed from public information. Nineteen of twenty-four cannot, and each is excluded with a published reason.
| Route | Monthly | Medication included | Basis |
|---|---|---|---|
| TRYM Health | $125 | Yes | complete published commitment ladder for the standard injection: medication incl |
| NexLife | $186 | Yes | complete published commitment ladder for the standard injection: medication incl |
| Fridays | $240 | Yes | advertised monthly rate with medication included and no separate membership fee |
| Mochi Health | $278 | Yes | effective recurring cost: medication plus every mandatory fee, computed from the |
| Eden | $298 | Yes | effective recurring cost: medication plus every mandatory fee, computed from the |
| Zepbound self-pay (2.5 mg) | $299 | Yes | Manufacturer direct channel |
| Zepbound self-pay (7.5 mg+) | $449 | Yes | Manufacturer direct channel |
| Zepbound retail, no coverage | ~$1,086 | Yes | Approximate list price |
What does the hidden-fee problem look like in practice?
A provider advertising $99 a month for medication with a $79 monthly membership costs $178. A provider publishing $186 all-in costs $186. The advertised figures differ by $87 in one direction; the real figures differ by $8 in the other. This is the single most common way GLP-1 pricing misleads.
It is why this site computes an effective monthly figure before ranking anything, and why providers whose fee structure is unstated are excluded rather than estimated.
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Recurring membership fee | $79 | $178 |
| Shipping, billed monthly | $10 | $188 |
What should you actually budget?
Model the recurring price over two to three years rather than the first month, because SURMOUNT-4 showed that stopping produces substantial regain. Then add the question almost everyone forgets: what the price becomes at a maintenance dose, since dose-related surcharges can change which option is cheapest by month six.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide cost 2026.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on what tirzepatide actually costs in 2026.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
How much does tirzepatide cost without insurance?
Zepbound self-pay through the manufacturer runs $299 per month at 2.5 mg and $449 at 7.5 mg and above, against a retail list price near $1,086.
Why is my quoted price different from the advertised one?
Advertised figures frequently cover medication only, with membership, consultation or shipping billed separately.
Is a 12-month prepayment worth it?
Only if you complete it. Discontinuation from side effects is common, and prepaid balances are frequently non-refundable.
Does the price change as my dose increases?
At some providers, yes. Dose-coverage terms are unverified for most, so ask directly.
What is the single highest-value thing I can do about cost?
Pursue insurance coverage if you have commercial insurance. A successful appeal outperforms any price comparison.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.